SCHEMBL4347399

SCHEMBL4347399

Cc1ccc(S(=O)(=O)n2ccc3nc(CNC(=O)C45CCC(NC(=O)O)(CC4)CC5)cnc32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 3/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
POLB P06746 2/20 0.33
PTPN11 Q06124 1/20 0.32
PKM P14618 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RECQL P46063 1/20 0.31
NPC1 O15118 1/20 0.31
HDAC3 O15379 2/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC2 Q92769 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
PPARG P37231 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351093 0.90 NAMPT (0.36) L3MBTL1SLC1A3SLC1A2SLC1A1POLB
SCHEMBL4350834 0.85 L3MBTL1 (0.34) L3MBTL1RAB9ASLC1A3SLC1A2SLC1A1
SCHEMBL2318672 0.84 L3MBTL1 (0.46) L3MBTL1RAB9ASLC1A3SLC1A2SLC1A1
SCHEMBL4357269 0.83 L3MBTL1 (0.38) L3MBTL1SLC1A3SLC1A2SLC1A1POLB
SCHEMBL2359779 0.80 L3MBTL1 (0.45) L3MBTL1RAB9ASLC1A3SLC1A2SLC1A1
SCHEMBL4347401 0.80 L3MBTL1 (0.38) L3MBTL1POLBPTPN11NPSR1ALDH1A1
SCHEMBL18855846 0.77 L3MBTL1 (0.49) L3MBTL1POLBPKMALDH1A1HPGD
SCHEMBL1536085 0.77 HPGD (0.47) POLBPKMNPSR1ALDH1A1LMNA
SCHEMBL12389611 0.77 CA12 (0.42) L3MBTL1POLBCA12CA1CA2
SCHEMBL20684438 0.76 L3MBTL1 (0.48) L3MBTL1POLBPKMALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 US disclosed
EP-3031324-A2 TRICYCLIC KINASE INHIBITORS AbbVie Inc. (US) 2016-06-15 EP disclosed
US-9365579-B2 Tricyclic compounds ABBVIE INC. (US) 2016-06-14 US disclosed
EP-2299821-B1 TRICYCLIC COMPOUNDS ABBVIE INC (US) 2015-11-04 EP disclosed
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2015-07-30 US disclosed
US-8962629-B2 Tricyclic compounds ABBVIE INC. (US) 2015-02-24 US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885RAB9A 1684/4885SLC1A3 2710/4885
US-20090312338-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885RAB9A 1684/4885SLC1A3 2710/4885
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885RAB9A 1684/4885SLC1A3 2710/4885
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885RAB9A 1684/4885SLC1A3 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.